Allergic Conjunctivitis - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
68 Pages - GMD12031
$2,000.00

Summary

Global Markets Direct’s, ‘Allergic Conjunctivitis - Pipeline Review, H1 2014’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Allergic Conjunctivitis Overview 7
Therapeutics Development 8
Pipeline Products for Allergic Conjunctivitis - Overview 8
Pipeline Products for Allergic Conjunctivitis - Comparative Analysis 9
Allergic Conjunctivitis - Therapeutics under Development by Companies 10
Allergic Conjunctivitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Allergic Conjunctivitis - Products under Development by Companies 15
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 16
Alcon, Inc. 16
Allergan, Inc. 17
Sun Pharmaceutical Industries Limited 18
Laboratoires Thea S.A. 19
Oxagen Limited 20
Celsus Therapeutics Plc 21
Laila Pharmaceuticals Pvt. Ltd. 22
Eleven Biotherapeutics 23
Ocular Therapeutix, Inc. 24
Griffin Discoveries BV 25
Allergic Conjunctivitis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AC-170 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AGN-229666 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dexamethasone acetate SR - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
OC-459 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SUN-1334 H - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
T-1210 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AL-53817 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
EBI-005 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LP-00209 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OPX-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Sun-0597 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule To Antagonize Histamine H1/H4 Receptor - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GD-134 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Allergic Conjunctivitis - Recent Pipeline Updates 52
Allergic Conjunctivitis - Dormant Projects 59
Allergic Conjunctivitis - Discontinued Products 61
Allergic Conjunctivitis - Product Development Milestones 62
Featured News & Press Releases 62
Mar 04, 2014: Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005 62
Nov 25, 2013: Santen Launches Alesion 0.05% Ophthalmic Solution for Allergic Conjunctivitis Treatment in Japan 63
Sep 20, 2013: Santen Announces Approval of Alesion 0.05% Ophthalmic Solution for Allergic conjunctivitis Treatment in Japan 63
Apr 17, 2013: Celsus Therapeutics Receives US Patent Covering Product Candidate OPX-1 For Treatment Of Conjunctivitis 63
Nov 27, 2012: Santen Pharma Files For Manufacturing And Marketing Approval Of Anti-Allergic Ophthalmic Solution, DE-114 64
Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico 64
Mar 22, 2011: ISTA Pharmaceuticals Highlights BEPREVE Clinical Data At 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting 64
Nov 26, 2010: Restasis gets Health Canada approval 65
Sep 16, 2010: Akorn Receives FDA Approval For Erythromycin Ophthalmic Ointment USP 1g 65
Jun 07, 2010: New Efficacy Data Emphasize The Benefit Of Pollinex Quattro Grass 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products under Development for Allergic Conjunctivitis, H1 2014 8
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Allergic Conjunctivitis - Pipeline by Alcon, Inc., H1 2014 16
Allergic Conjunctivitis - Pipeline by Allergan, Inc., H1 2014 17
Allergic Conjunctivitis - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 18
Allergic Conjunctivitis - Pipeline by Laboratoires Thea S.A., H1 2014 19
Allergic Conjunctivitis - Pipeline by Oxagen Limited, H1 2014 20
Allergic Conjunctivitis - Pipeline by Celsus Therapeutics Plc, H1 2014 21
Allergic Conjunctivitis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 22
Allergic Conjunctivitis - Pipeline by Eleven Biotherapeutics, H1 2014 23
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2014 24
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2014 52
Allergic Conjunctivitis - Dormant Projects, H1 2014 59
Allergic Conjunctivitis - Dormant Projects (Contd..1), H1 2014 60
Allergic Conjunctivitis - Discontinued Products, H1 2014 61

List of Figures
Number of Products under Development for Allergic Conjunctivitis, H1 2014 8
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax